Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9254523 | 0.85 | PRMT6 (0.55) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL2586836 | 0.81 | AGXT (0.45) | PRMT6ACMSD | |
| SCHEMBL9171384 | 0.80 | PRMT6 (0.52) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL30340237 | 0.79 | PRMT6 (0.68) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL9846347 | 0.79 | PRMT6 (0.63) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL9454377 | 0.79 | PRMT6 (0.63) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL112601 | 0.79 | PRMT6 (0.63) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL4171349 | 0.79 | PRMT6 (0.63) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL10162041 | 0.79 | PRMT6 (0.68) | PRMT6DRD2DRD4DRD3CYP2A6 | |
| SCHEMBL7499054 | 0.79 | PRMT6 (0.63) | PRMT6DRD2DRD4DRD3CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| CN-1902186-B | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG | 2010-12-22 | — | — | CN | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| CN-1902186-A | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | PRMT6 939/4885DRD2 3880/4885DRD4 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.